Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D., and CFO Alexandra Balcom will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 1:30 p.m. ET in New York City.

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D., and CFO Alexandra Balcom will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 1:30 p.m. ET in New York City.

A live webcast will be available in the Investors section of Nuvalent's website and archived for 30 days after the presentation.

Argus Feb 5 session

-3.90% close to close Open Argus

Details

News Market Reaction – NUVL

On Feb 5, the day this news came out, NUVL closed 3.90% below the previous close.

Data tracked by StockTitan Argus for the Feb 5 session.

Market Context

This announcement focuses on Nuvalent’s participation in the Guggenheim Emerging Outlook: Biotech Su...

Analysis

This announcement focuses on Nuvalent’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, where leadership will join a fireside chat with a webcast archived for 30 days. It adds to a series of investor-facing events following the OnTarget 2026 operating plan update and prior conference appearances. Context includes a recent $500.0 million equity offering and a preliminary $1.4 billion cash estimate, which frame Nuvalent’s capital position as it continues to communicate its longer-term plans.

Key Figures

Current share price: $104.99 52-week high: $113.015 52-week low: $55.535 +5 more

Current share price

$104.99

Pre-news price for NUVL

52-week high

$113.015

Pre-news 52-week high level

52-week low

$55.535

Pre-news 52-week low level

Cash and securities

$1.4 billion

Preliminary estimate as of Dec 31, 2025 from 8-K

Equity offering size

4,950,496 shares

Public offering of Class A common stock at $101.00 per share

Gross offering proceeds

$500.0 million

Gross proceeds before fees from Nov 20, 2025 offering

Additional shares sold

742,574 shares

Additional shares sold by selling stockholders; no proceeds to Nuvalent

Webcast archive period

30 days

Summit fireside chat webcast availability

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Operating plan update

   24h Move

   -5.6%

   Outlined 2026 milestones and preliminarily estimated $1.4B cash funding into 2029.

2. Dec 22

   Conference participation

   24h Move

   +1.9%

   Announced CEO presentation at 44th J.P. Morgan Healthcare Conference with webcast access.

3. Dec 10

   Board appointment

   24h Move

   +0.2%

   Added experienced oncology executive Ron Squarer to Board to support commercialization plans.

4. Nov 26

   Conference participation

   24h Move

   -0.7%

   Planned fireside chat at Piper Sandler healthcare conference with 30-day archived webcast.

5. Nov 24

   Equity offering

   24h Move

   +0.3%

   Closed public offering of 4.95M shares at $101, raising about $500M gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC.

A live webcast will be available in the Investors section of Nuvalent's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026-302679634.html

SOURCE Nuvalent, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nuvalent (NUVL) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Nuvalent will present on Thursday, February 12, 2026 at 1:30 p.m. ET. According to Nuvalent, the session is a fireside chat featuring the CEO and CFO in New York City at the summit.

Who from Nuvalent (NUVL) will participate in the fireside chat on February 12, 2026?

James Porter, Ph.D., CEO, and Alexandra Balcom, CFO, will participate in the fireside chat. According to Nuvalent, both executives will speak and answer investor-focused questions at the summit.

How can investors watch Nuvalent's (NUVL) Guggenheim Biotech Summit presentation if they cannot attend?

A live webcast will be available via the Investors section of Nuvalent's website. According to Nuvalent, the webcast will be archived for 30 days after the presentation for on-demand viewing.

Will Nuvalent (NUVL) archive the Guggenheim summit webcast and for how long?

Yes, the webcast will be archived for 30 days following the presentation. According to Nuvalent, the archived video will remain accessible in the Investors section of the company website for that period.

What topics will Nuvalent (NUVL) executives likely cover during the Guggenheim Biotech Summit fireside chat?

The session will focus on the company's clinical-stage programs and corporate strategy, led by CEO and CFO remarks. According to Nuvalent, the chat will present updates and investor-relevant discussion at the summit.